CTOs on the Move

RareCyte

www.rarecyte.com

 
RareCyte is a company focused on characterizing and isolating rare cells from blood.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

RareCyte raised $30M on 08/29/2017
RareCyte raised $22M on 12/19/2019

Similar Companies

UBC Heart + Lung Institute

UBC Heart + Lung Institute is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioMx

BioMx is a South Amboy, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Premiera Care Communities

Premiera Care Communities is a Oakdale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ignyta

Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases

Vaxin

Vaxin is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Vaxin is able to rationally design and rapidly develop immunotherapeutic products tailored to address the a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer with fundamental advantages over competing products. Our mission at Vaxin is to protect and preserve public health by providing effective and safe vaccines that prevent disease outbreak.